|
Variables
|
Number (n = 61)
|
c-Met expression
|
P-values
|
|---|
|
Positive
|
Negative
|
|---|
|
Gender
|
|
Male
|
41 (67.2%)
|
20 (60.6%)
|
21 (75.0%)
|
0.233†
|
|
Female
|
20 (32.8%)
|
13 (39.4%)
|
7 (25.0%)
| |
|
Median age (range)
|
62 (36–81)
|
61 (36–74)
|
64 (38–81)
|
0.541#
|
|
Pathological types
|
|
WDA
|
17 (27.9%)
|
12 (36.4%)
|
5 (17.9%)
|
0.373†
|
|
MDA
|
18 (29.5%)
|
9 (27.3%)
|
9 (32.1%)
| |
|
PDA
|
21 (34.4%)
|
9 (27.3%)
|
12 (42.9%)
| |
|
MAC/SRC
|
5 (8.2%)
|
3 (9.1%)
|
2 (7.1%)
| |
|
Lauren classifications
|
|
Intestinal
|
23 (46.9%)
|
13 (48.1%)
|
10 (45.5%)
|
0.851†
|
|
Non-intestinal
|
26 (53.1%)
|
14 (51.9%)
|
12 (54.5%)
| |
|
Baseline CEA (ng/ml)
|
|
Median (range)
|
2.9 (0.4–776.4)
|
2.9 (0.4–776.4)
|
3.1 (1.1–242.0)
|
0.399#
|
|
Baseline CA19–9 (U/ml)
| | | |
|
Median (range)
|
9.0 (0.6–597.4)
|
8.4 (0.6–597.4)
|
10.1 (0.6–69.2)
|
0.510#
|
|
Baseline CA72–4 (U/ml)
|
|
Median (range)
|
2.8 (0.8–131.2)
|
3.2 (0.8–131.2)
|
2.0 (0.9–79.3)
|
0.288#
|
|
Findings on PET/CT
|
|
Locoregional
|
26 (42.6%)
|
11 (33.3%)
|
15 (53.6%)
|
0.111†
|
|
Distant metastasis
|
35 (57.4%)
|
22 (66.7%)
|
13 (46.4%)
| |
|
SUVmax (mean ± SD)
|
8.8 ± 6.40
|
9.6 ± 7.40
|
8.0 ± 4.91
|
0.335*
|
|
SUVpeak (mean ± SD)
|
7.2 ± 5.22
|
7.7 ± 5.99
|
6.6 ± 4.08
|
0.438*
|
|
MTV (mL, mean ± SD)
|
57.4 ± 54.39
|
70.8 ± 53.11
|
41.1 ± 52.32
|
0.034*
|
|
TLG (g, mean ± SD)
|
328.2 ± 417.44
|
428.4 ± 442.95
|
205.7 ± 354.40
|
0.039*
|
|
PFS, Median (95%CI)
|
14.5 (2.0–82.2)
|
11.5 (7.8–15.2)
|
17.6 (15.1–20.1)
|
0.039‡
|
|
OS, Median (95%CI)
|
20.0 (5–86.2)
|
17.0 (13.9–20.5)
|
24.3 (17.0–31.6)
|
0.043‡
|
- Note. SD standard deviation, CA19–9 carbohydrate antigen 19–9, CA72–4 carbohydrate antigen 72–4, CEA carcinoembryonic antigen, WDA well differentiated adenocarcinoma, MDA moderate differentiated adenocarcinoma, PDA poorly differentiated adenocarcinoma, SRC signet-ring cell carcinoma, MAC mucinous adenocarcinoma, PET/CT positron emission tomography/computed tomography, SUV standardized uptake value, Max maximum, MTV metabolic tumor volume, TLG total lesion glycolysis, PFS progression free survival, OS overall survival. *, Student’s t test; †, Chi square test; ‡, Kaplan-Meier analysis with the log-rank test; #, Mann-Whitney U test
